Mainz Biomed

About Mainz Biomed

Mainz Biomed is dedicated to saving lives by transforming at-home cancer detection. Founded in Germany, it is becoming a leading global provider of easy-to-use diagnostic solutions for patients and healthcare providers, focusing on early identification of deadly conditions like colorectal and pancreatic cancer with simple, readily available, and affordable products.

Products & Services

ColoAlert:An innovative product designed for quick and reliable early detection of colorectal cancer (CRC).

NextGen Colorectal Cancer Screening:An advanced screening solution for colorectal cancer, with an accelerated FDA pathway as of 2025.

Pancreatic Cancer Screening:A diagnostic solution for early detection of pancreatic cancer, recently expanded through acquisition.

Specialties

Cancer Detection Colorectal Cancer Screening Pancreatic Cancer Screening Diagnostic Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 6000000 MR: - FA: 6.0 million USD FAN: 6000000	D: 2026-02-17 FD: 2026-02-17	1 investors
2	RT: Follow-On Offering T: - FT: Follow-On Offering	A: 3000000 MR: - FA: approximately $3.0 million FAN: 3000000	D: 2025-08-04 FD: 2025-08-04	-
3	RT: Follow-On Offering T: - FT: Follow-On Offering	A: 4000000 MR: - FA: approximately $4.0 million FAN: 4000000	D: 2025-05-19 FD: 2025-05-19	1 investors
4	RT: Follow-on Offering T: - FT: Follow-on Offering	A: 8000000 MR: - FA: approximately $8.0 million FAN: 8000000	D: 2024-12-16 FD: 2024-12-16	1 investors
5	RT: Follow-on Offering T: - FT: Follow-on Offering	A: 8000000 MR: - FA: approximately $8.0 million FAN: 8000000	D: 2024-12-12 FD: 2024-12-12	-
6	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: $5.0 million FAN: 5000000	D: 2023-11-15 FD: 2023-11-15	1 investors
7	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 5000000 MR: - FA: $5.0 million FAN: 5000000	D: 2023-11-13 FD: 2023-11-13	1 investors
8	RT: Debt T: - FT: Debt	A: 50000000 MR: - FA: up to $50 million FAN: 50000000	D: 2023-06-29 FD: 2023-06-29	1 investors

Private Placement Latest

2026-02-17

$6.0M

1 investor (Pro only)

Follow-On Offering 2025-08-04

$3.0M

Follow-On Offering 2025-05-19

$4.0M

View 7 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Dollinger MM

G

Guido Baechler

CEO & Director

W

William Caragol

CFO

M

Moritz Eidens

Chief Scientific Officer

P

Philipp Freese

CBO

C

Chris von Törne

COO

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Mainz Biomed Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised